Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial
Conclusions The study met the primary objective. RP2D was capecitabine 800 mg/m2 bid continuously, erlotinib 150 mg daily, and bevacizumab 10 mg/kg q 2 weeks. The regimen could be applied safely, but demonstrated limited efficacy.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Adenocarcinoma | Avastin | Cardiology | Cardiovascular | Drugs & Pharmacology | Gastroenterology | Heart | Hematology | Investigational New Drugs | Nutrition | Pancreas | Study | Tarceva | Toxicology | Xeloda